YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Myriad Genetics, Inc. SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a c…
BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support pr…
SOPHiA GENETICS SA SOPH shares rallied 7% in the last trading session to close at $8.53. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.…
(RTTNews) - The following biotech stocks reached a 52-week high on August 4, 2026, driven by key catalysts like positive quarterly results or certain regulatory milestones. UFP Technologies Inc. (UFPT) UFP Technologies is a contract develo…
[Wall Street-Street Sign] P_Wei/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-up moves before the bell on Tuesday. Stock index futures (SPX [https://seekingalpha.com/symbol/SPX]) were higher before the bell Tues…
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies…
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies…
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies…
Tempus AI, Inc. TEM is expected to report second-quarter 2026 results on June 30, after market close. In the last reported quarter, the company's adjusted loss of 13 cents per share was narrower than the Zacks Consensus Estimate of a loss…
(RTTNews) - The following biotech stocks reached a 52-week high on July 20, 2026, driven by key catalysts such as upcoming clinical trial launches and the prospective release of data from these studies. Xencor Inc. (XNCR) Xencor is a clini…
(RTTNews) - SOPHiA GENETICS SA (SOPH), a cloud-native healthcare technology, on Friday said it closed a $57 million public offering of shares announced on June 16. The offering was oversubscribed, and the underwriters exercised in full the…
(RTTNews) - SOPHiA GENETICS SA (SOPH), an AI-driven precision medicine company, on Tuesday announced pricing of an underwritten public offering. The company is issuing 6,508,650 ordinary shares at a public offering price of $4.75 per share…
[Close-up of male professional hands using mobile phone] Luis Alvarez Stock futures inched higher in premarket trading Wednesday as investors geared up for a much-anticipated Federal Reserve rate decision and awaited more clarity on a prel…
* SOPHiA GENETICS (SOPH [https://seekingalpha.com/symbol/SOPH]) priced a public offering of 10.53M ordinary shares at $4.75 per share. * The company has raised about $50M in gross proceeds, with underwriters receiving a 30-day option to bu…
[Stock market activity shows price changes and trading movements in real time] FabrikaCr Wall Street’s major market averages ended mixed on Tuesday after the U.S.-Iran peace deal lifted sentiment in the previous session. The blue chip Dow…
SOPHiA GENETICS S.A. Q1 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Management attributes the 22% revenue growth to a global shift toward decentralized testing, particularly in the U.S. where established rei…
Image source: The Motley Fool. DATE Tuesday, May 5, 2026 at 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Jurgi Camblong Chief Financial Officer — George Cardoza Chief Executive Officer (Incoming), Chief Business Officer — Ross Muk…
SOPHiA GENETICS SA (NASDAQ:SOPH) is one of the 8 Best Healthcare AI Stocks to Buy According to Analysts. On April 15, 2026, BTIG raised its price target on SOPHiA GENETICS SA (NASDAQ:SOPH) to $8 from $7 and maintained a Buy rating. The fir…
Tempus AI, Inc. TEM is expected to report first-quarter 2026 results on May 5, after market close. In the last reported quarter, the company’s adjusted loss of 4 cents per share was broader than the Zacks Consensus Estimate of a loss of 2…
Tempus AI’s TEM Data and Applications segment has emerged as a central pillar of the company’s business, which is built on two main components — data licensing (Insights) and a growing suite of software-driven applications. The Data and Ap…
SOPHiA GENETICS S.A. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Platform Evolution Achieved 22% total revenue growth in Q4 2025, driven by a 31% increase in clinical revenue as the core business re-accelerated toward hist…
Image source: The Motley Fool. DATE March 3, 2026, 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Jurgi CamblongChief Financial Officer — George A. CardozaChief Operating Officer — Ross MukenHead of Investor Relations — Kellen Sange…
Image source: The Motley Fool. DATE March 3, 2026, 8 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Jurgi Camblong Chief Financial Officer — George A. Cardoza Chief Operating Officer — Ross Muken Head of Investor Relations — Kellen Sa…
Tempus AI, Inc. TEM is expected to report fourth-quarter 2025 results on Feb. 24. In the last reported quarter, the company’s adjusted loss of 11 cents per share was narrower than the Zacks Consensus Estimate of a loss of 16 cents. Tempus…
(RTTNews) - Several biotechnology and life sciences companies posted notable gains in after-hours trading on Friday, reflecting investor interest in recent clinical and corporate developments. Kura Oncology, Inc. (KURA) led the group with…
Tempus AI’s TEM third-quarter 2025 results highlight the growing strategic importance of its Insights and Data & Services business, which is emerging as a high-margin and scalable revenue stream beyond traditional genomic testing. Data and…
Myriad Genetics, Inc. Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations. Third quarte…
Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Network Access Control (NAC) Hardware - A Global Market Overview" has been added to ResearchAndMarkets.com's offering. The Network Access Control (NAC) hardware market is experiencing a signif…
BCC Research LLC “BCC Research analyzes how AI-driven discovery tools, predictive analytics, and scalable cloud platforms are transforming biotechnology's future.” Boston, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Artificial intelligence (AI) is t…
Company Logo AI in biotechnology is rapidly transforming genetic engineering, personalized medicine, and drug discovery by enabling faster and precise operations. Key opportunities lie in AI-driven predictive analytics, optimization of man…
SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision…
BOSTON, Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & C…
Tempus AI, Inc. TEM is rapidly expanding its partnerships across oncology and neuroscience, leveraging its AI platforms — Lens and Next — to accelerate precision medicine. Tempus has entered into a multi-year collaboration with The Abrams…
As the U.S. stock market faces a pause in its rally, with major indices like the S&P 500 and Nasdaq Composite experiencing slight declines amid concerns over tariffs and economic outlooks, investors are increasingly looking at alternative…
Earnings Call Insights: SOPHiA GENETICS SA (SOPH) Q2 2025 MANAGEMENT VIEW * CEO Jurgi Camblong reported, "revenue growth continued to reaccelerate and cash burn decreased notably," highlighting that total revenue grew 16% year-over-year, a…
* Sophia Genetics (NASDAQ:SOPH [https://seekingalpha.com/symbol/SOPH]) filed $200M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10270651] MORE ON SOPHIA GENETICS * Seeking Alpha’s Quant Rating on SOPHiA Genetics [https…